AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01321463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablet once daily for 12 weeks
Study NCT00045903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure and Ritual Prevention (Cognitive Behavioral Therapy)
Study NCT00045903 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management Therapy (Cognitive Behavior Therapy)
Study NCT02743234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: FMT follows 4-10 days of vancomycin 125 mg x 4 daily
Study NCT03810378 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (Med-Plus)
Description: Participants will follow the Med-Plus diet for 12 weeks, then switch to the alternate diet for another 12 weeks (no washout period).
Study NCT03810378 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Well-Formulated Ketogenic Diet (WFKD)
Description: Participants will follow the WFKD diet for 12 weeks, then switch to the alternate diet for another 12 weeks (no washout period).
Study NCT03029676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: benzodiazepines
Description: sedative
Study NCT03029676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: opioid
Description: analgetic, sedative
Study NCT03029676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: opioid
Description: analgetic, sedative
Study NCT03029676 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Study NCT03369015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo dose given (double-blind) and behavioral tasks (EEfRT, PRT, ELT, CGT) administered.
Study NCT03029676 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia
Study NCT01988597 — intervention group
Intervention type: OTHER
Intervention: Dry eyes
Study NCT00706394 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endologix Powerlink 34 mm stent graft cuff
Description: Endovascular abdominal aortic aneurysm repair
Study NCT04432740 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Treatment of Distal Radius Fracture
Description: The purpose of this prospective randomized study was to compare a new reverse sugar tong splint technique that does not immobilize the elbow with a below-arm cast, in terms of patient radiological and clinical outcomes and the ability to maintain fracture reduction.
Study NCT00430898 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Basiliximab
Description: 3 doses of 40mg, IV at baseline, week 2, and week 4
Study NCT00430898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: 3 doses of 40mg, IV at baseline, week 2, and week 4
Study NCT02925312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Pathway
Description: Medication algorithm, survival skills education, enhanced patient-provider communication facilitated by near, real-time blood glucose monitoring
Study NCT04724681 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WARD CSS
Description: Wireless devices monitor vital signs continuously and transmit real-time data to an app that notifies clinical personnel when relevant deviations in vital signs occur This group will be monitored with standard Early Warning Score as well
Study NCT03091699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Participants will be required to smoke a cigarette to completion in a 20 minute time frame.
Study NCT02743234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fidaxomicin
Description: Fidaxomicin 200 mg x 2 daily for 10 days
Study NCT02743234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin 125 mg x 4 daily for 10 days
Study NCT03091699 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Exercise
Description: Participants will be required to perform 20 minutes of acute moderate intensity exercise (brisk walk) on a treadmill.
Study NCT02381548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Given PO
Study NCT02381548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Given IV
Study NCT02381548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02381548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01171287 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Driving with an Aircast Walker
Study NCT01171287 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Driving with a walking cast
Study NCT01171287 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Driving with a running shoe
Study NCT04231513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2814
Description: E2814, intravenous infusion.
Study NCT01722344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Placement and support (IPS)
Description: IPS involves an employment specialist who is integrated within the mental health team, and carries out all phases of the vocational services, with a caseload on less than 25. The intervention is based on the 7 principles of IPS Supported Employment. The essence of these principles is an individualized and rapid search for competitive employment or education that avoids prolonged prevocational training and preparation. The intervention is integrated within the mental health services, with emphasis on client preference and choice regarding jobs, and with availability of on going job support and benefit counselling
Study NCT03861403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRX518
Description: Administered by IV infusion
Study NCT03861403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered by IV infusion
Study NCT03861403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Administered by IV infusion
Study NCT03601650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful eating
Description: Attending to the sensory properties of food as it is eaten
Study NCT03601650 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eating without distractions
Description: Eating without intentionally attending to something else such as a television, smartphone, computer, book etc
Study NCT02351310 — intervention group
Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Course of placebo drug given intramuscularly (2 doses of normal saline (of equal quantity) 24 hours apart).
Study NCT03208881 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Dietary Supplement: Intensive dietary intervention
Description: Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
Study NCT03751956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: The subjects will receive an intravenous injection of 0.8 μCi/0.4 mg/kg of \[14C\]HSK3486 emulsion injection (i.e., a subject with the body weight of 60 kg is administered with a radiation dose of 48 μCi).
Study NCT03067142 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Not an interventional study. Analyses of previously collected urine specimens and data on estimated kidney filtering function.
Study NCT01722344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPS plus
Description: Individual Placement and Support + cognitive remediation and work-related social skills training, consists of the IPS intervention + 24 sessions of computer based cognitive training and 24 group based sessions of cognitive coping strategies and work-related social skills training.
Study NCT01212471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromfenac Ophthalmic Solution A
Description: sterile ophthalmic solution
Study NCT04231513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2814-matched placebo
Description: E2814-matched placebo, intravenous infusion.
Study NCT00769093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferumoxytol
Description: 2 mg/kg
Study NCT01212471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromfenac Ophthalmic Solution B
Description: sterile ophthalmic solution
Study NCT01212471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: sterile ophthalmic solution
Study NCT00976638 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chromogenic surveillance
Description: All admitted patients are screened on admission for MRSA and VRE by chromogenic agar and isolated when positive
Study NCT00295295 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High frequency, low magnitude vibration
Description: High frequency, low magnitude vibration at 30 Hz, 10 min/day using vibrating platform from Juvent Medical Inc.
Study NCT00295295 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standing
Description: Standing 10 min/day
Study NCT04428333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feladilimab
Description: Humanized anti-inducible T cell co-stimulatory receptor (ICOS) immunoglobulin G4 (IgG4) monoclonal antibody (mAb)
Study NCT04428333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized anti- programmed cell death receptor1 (anti-PD-1) IgG4 mAb
Study NCT04428333 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab
Description: Humanized anti- programmed cell death receptor1 (anti-PD-1) IgG4 mAb
Study NCT04428333 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline
Study NCT04428333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum based chemotherapy
Description: Cisplatin/carboplatin
Study NCT04428333 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Platinum based chemotherapy
Description: Cisplatin/carboplatin
Study NCT04428333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5FU)
Description: 5-fluorouracil
Study NCT04428333 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluorouracil (5FU)
Description: 5-fluorouracil
Study NCT01936623 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Brief Intervention
Description: No additional information needed.
Study NCT01936623 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Computerized Brief Intervention
Description: No additional information needed.
Study NCT03559166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLD-2660
Description: Randomized to active product or placebo
Study NCT03559166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BLD-2660
Description: Randomized to active product or placebo
Study NCT03452085 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: artificial saliva spray (AS)
Description: cross over design
Study NCT01271751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFT505 80mg
Description: hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast
Study NCT01271751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: hard gelatin capsules, oral administration, 4 capsules per day before breakfast
Study NCT00976638 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Molecular surveillance
Description: All patients are screened for MRSA and VRE by PCR; and for ESBL by chromogenic agar on admission. Positive patients are isolated
Study NCT01791660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zeltiq Coolsculpting System
Description: Non-invasive device designed to cool subcutaneous fat without affecting adjacent or underlying structures.
Study NCT03191162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benznidazole
Description: To evaluate different regimens of Benznidazole for the treatment of chronic Chagas disease
Study NCT03191162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benznidazole
Description: To evaluate different regimens of Benznidazole for the treatment of chronic Chagas disease
Study NCT06090630 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diffusion Weighted Imaging
Description: Undergo DWI-MRI
Study NCT06090630 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Undergo MR spectroscopic imaging
Study NCT01106157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globin (ATG)
Description: Anti-Thymocyte Globin (ATG) will be given as 0.5/mg/kg on day 1 and 2mg/kg on day 2.
Study NCT01106157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline infusions will be given on Day 1 and Day 2 followed by placebo injections given in identical volumes in identical syringes
Study NCT01106157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated GCSF
Description: 6 doses of pegylated GCSF (6mg/dose) will be given subcutaneously every 2 weeks beginning after the ATG infusion.
Study NCT03230318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: derazantinib
Description: Derazantinib was administered orally at 300 mg once daily
Study NCT02705482 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI0562
Description: Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
Study NCT02705482 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
Study NCT02705482 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
Study NCT02075424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: salivary sampling by a biomnis swab
Description: Each call operator will have a series of salivary sampling taken when assigned to call reception, to the unit deployment station and to the assessment station.~Only one sampling will occur to doctors who are assigned to a single workstation.~Sampling will be taken every 15 minutes during one hour and half and one last sample will be taken 2 hours after the call.~To improve interpretation of the results, a series of control-samples will be taken among the call operators and doctors during a day off and not during a security break.~There will be 4x8 samples taken for each call operator and 2x8 samples per doctor.~They will also be frozen at a temperature of -4°C and sent to the laboratory of the CHR Metz Thionville.
Study NCT00885183 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Acupuncture therapy
Description: 12 acupuncture treatment sessions for a period of 16 weeks
Study NCT00885183 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy
Description: 12 acupuncture treatment sessions for a period of 16 weeks
Study NCT01234181 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypoxia-stressed BMSCs transplantation to cure MI
Description: Experimental group: intracoronary injection of 10\^7 BMSCs Sham Comparator: inject the same volume saline
Study NCT01234181 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Hypoxia-stressed BMSCs transplantation to cure MI
Description: Experimental group: intracoronary injection of 10\^7 BMSCs Sham Comparator: inject the same volume saline
Study NCT02137642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RM-131
Description: Double blind RM-131 (100 ug) will be delivered once by injection during study procedure.
Study NCT02659475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHEN/TPM ER (Qsymia®)
Description: PHEN/TPM ER (Qsymia®)
Study NCT02137642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double blind placebo will be delivered once by injection during study procedure.
Study NCT00572416 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Sleep Promotion Plan
Description: Four components, including activity-rest, sleep-wake, psychological distress, and symptom management. Sleep-wake component has four strategies: stimulus control, sleep restriction, relaxation, and sleep hygiene
Study NCT00572416 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Healthy Eating Control
Description: Equal time and attention and information about healthy eating
Study NCT02141672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voclosporin High Dose
Study NCT02048267 — intervention group
Intervention type: PROCEDURE
Intervention: Frey's procedure/Pylorus preserving pancreatoduodenectomy
Description: Duodenum preserving head resection
Study NCT02141672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voclosporin Low Dose
Study NCT02141672 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02512289 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS (ELDITH) and RAT (REAplan)
Description: Transcranial direct-current stimulation( ELDITH) and Robot-assisted therapy by using REAplan
Study NCT02512289 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS (ELDITH) and RAT (REAplan)
Description: Transcranial direct-current stimulation( ELDITH) and Robot-assisted therapy by using REAplan
Study NCT02688192 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Participate in fitness program
Study NCT02688192 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-Based Intervention
Description: Engage in private social support messaging and Use the mobile app
Study NCT02688192 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring Device
Description: Wear an electronic accelerometer
Study NCT02688192 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03805854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 10 Hz tACS of the bilateral somatosensory cortex
Description: 10 Hz tACS at 1 mA will be applied over the bilateral somatosensory cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions CP3 and CP4 according to the international 10-20 system.
Study NCT03805854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 10 Hz tACS of the prefrontal cortex
Description: 10 Hz tACS at 1 mA will be applied over the prefrontal cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions F3 and F4 according to the international 10-20 system.
Study NCT03805854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 80 Hz tACS of the bilateral somatosensory cortex
Description: 80 Hz tACS at 1 mA will be applied over the bilateral somatosensory cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions CP3 and CP4 according to the international 10-20 system.
Study NCT03805854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 80 Hz tACS of the prefrontal cortex
Description: 80 Hz tACS at 1 mA will be applied over the prefrontal cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions F3 and F4 according to the international 10-20 system.
Study NCT03805854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham stimulation of the bilateral somatosensory cortex
Description: 10 Hz tACS at 1 mA will be applied over the bilateral somatosensory cortex for 10 seconds at the beginning of the experimental session using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions CP3 and CP4 according to the international 10-20 system.
Study NCT03037307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product
Description: Five strips of test adhesive cream for upper denture, as per application instructions.